India is emerging as a global hub for advanced structural heart interventions with ‘Make in India’ revolutionary therapy, cost-effective access, skilled specialists, and growing awareness, according to experts. Four leading specialists from Heart Valve Experts (HVE) under HVS Hospitals, Mumbai highlighted the transformative potential of minimally invasive structural heart therapies of valvular regurgitation (Leak in valves) such as Myclip for high-risk cardiac patients who are unsuitable for conventional open-heart surgery or bypass procedures.

Speaking to the media in New Delhi after attending a high-level scientific conference on Minimally Invasive Structural Heart Solutions, the experts said India is steadily emerging as one of the key global destinations for advanced structural heart care alongside the United States and China.

The interaction was addressed by interventional cardiologists Dr Ankur Phatarpekar, Dr Meghav Shah, Dr Amit Gangwani and cardiac anesthetist Dr Gourish Shinde from HVE under HVS Hospitals.

The doctors explained that Myclip therapy is designed for selected patients suffering from severe mitral valve regurgitation. This is a condition where the heart valve leaks significantly, leading to breathlessness, fatigue, swelling and progressive heart failure. Many such patients are considered too high-risk for open-heart surgery because of advanced age, weak heart function or multiple medical complications.

Referring to the evolution of structural heart interventions in India, the experts pointed out that while the procedure had been available at select Centres of Excellence since 2018 using imported high-cost technologies from the United States, affordability remained a major challenge.

Dr Phatarpekar emphasised that patient selection remains the most critical aspect of such therapies.

Source: Express Healthcare - May 13,2026